The Health Bank to Partner with Nanotronics Health, LLC, to Distribute Low-Cost, US-Manufactured Non-Invasive Ventilator for Respiratory Support During COVID-19 Pandemic
17.8.2020 12:30:00 EEST | Business Wire | Press release
Salman Arif, the CEO of The Health Bank (THB) Global, announced today that the company is partnering with Nanotronics Health, LLC, to distribute nHaleTM, a non-invasive ventilator. It will be distributed in the Middle East, North Africa and South Asia (MENASA) region. To support non-invasive respiratory therapy in the region, The Health Bank will also train medical professionals to operate the device.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200817005113/en/
“In pursuit of finding a solution for managing COVID-19 symptoms through non-invasive methods, we have partnered with Nanotronics Health, LLC, for the sale and distribution of the nHaleTM. This partnership makes nHaleTM accessible in the Middle East, North Africa, and South Asia (MENASA) region, benefiting patients and health care providers with an affordable, high-quality solution,” said Zarmina Jafar, Head of Strategy at THB Global.
Nanotronics Health, LLC, obtained Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for nHaleTM for use in traditional healthcare facilities, spaces converted for the care of large numbers of COVID-19 patients, and in at-home settings with a doctor’s prescription. This authorization includes the optional use of supplemental oxygen in tandem with nHale™ when a qualified medical professional prescribes it.
Non-invasive ventilation is critical for COVID-19 patient care in the hospital and beyond. To meet this need, Nanotronics Health, LLC, leveraged Nanotronics’ deep in-house expertise, incorporating advanced AI, Intelligent Factory Control (IFC) and sophisticated engineering to conceive, design and manufacture nHaleTM in under 90 days.
“We developed nHaleTM to meet the urgent need for non-invasive respiratory options for patients suffering from COVID-19,” said Julie Orlando, President of Nanotronics Health, LLC. “We designed for quality, comfort and ease of use, making nHaleTM available at a fraction of the cost of other non-invasive ventilators.”
Nanotronics Health, LLC, developed and designed nHale™ to assist spontaneously breathing adults suffering from COVID-19 disease. It is intended for use in non-life-threatening situations, such as a patient in need of breathing assistance but not in need of invasive ventilatory support based on standard medical protocols.
About The Heath Bank
The Health Bank (THB) is a tech-enabled global health management company that offers individuals, families, and corporations a variety of virtual hospital services to support and manage their health and wellness. With a strong focus on prevention and wellness, we empower our members to be proactive about attaining and maintaining a healthy lifestyle, while preventing illness and disease, through our precision medicine and telemonitoring programs.
Our expertise in personalized healthcare delivery offers members and their loved ones peace of mind when facing any chronic or acute healthcare challenge, no matter how complex.
About Nanotronics Health, LLC
Nanotronics Health, LLC, is a subsidiary of and powered by Nanotronics. The company uses Intelligent Factory Control (IFC) to build and scale medical devices that are affordable, accessible and well-designed. Our first product, nHale™, a non-invasive ventilator, was conceived, built, and obtained Emergency Use Authorization by the FDA within 90 days to treat patients suffering from COVID-19. After obtaining Emergency Use Authorization, Nanotronics Health, LLC, immediately began producing and shipping devices.
About nHaleTM
nHale™ is a bi-level positive air pressure device to support respiratory therapy of spontaneously breathing adults weighing over 30kg suffering from COVID-19 disease. It is a non-invasive ventilator designed to be used in non-life-threatening situations, for spontaneously breathing patients, such as a patient in need of breathing assistance but not in need of invasive ventilatory support based on standard medical protocols.
The machine is for use in traditional healthcare facilities (e.g., hospitals, assisted living facilities, nursing homes) as well as spaces converted for the care of large numbers of COVID-19 patients (e.g., convention centers, university dormitories, motels, etc.). nHale™ is also intended for use in home settings with a doctor’s prescription.
Supplemental oxygen may be used with the nHale™ device to increase the oxygen concentration of the airflow being delivered to the patient only when prescribed and trained by a qualified medical professional. The warnings must be observed when using supplemental oxygen with the nHale™ device.
Nanotronics Health LLC, a subsidiary of Nanotronics, applied Nanotronics’ deep in-house expertise, incorporating advanced AI, Intelligent Factory Control (IFC), and sophisticated engineering to build a machine that is easily manufactured at scale and at a reduced cost to increase accessibility for all Americans. nHale™ is designed for comfort and ease-of-use with the simplicity of one button.
nHale™ has been authorized by FDA under an Emergency Use Authorization [EUA]; nHale™ is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the device; nHale™ has not been FDA cleared or approved.
nHale™ is a trademark of Nanotronics in the U.S. which can be found at nanotronics.co/nhale.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200817005113/en/
Contact information
Zarmina Jafar, Head of Strategy, The Health Bank
Zarmina@thbglobal.com; +97.15.05.13.13.00
Mary Cunney, Chief Communications Officer, Nanotronics
MCunney@nanotronics.co; 212.401.6209
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
